|
Business Daily from THE HINDU group of publications Friday, September 26, 2008 ePaper | Mobile/PDA Version | Audio |
|
|
|
|
|
Update at 1930 hrs (IST)
Industry Pharma outsourcing industry to cross $2.5 bn by 2012: Zinnov New Delhi, Sep 25 (PTI) Driven by the cost advantage and a better availability of talent pool, the total Indian pharmaceutical outsourcing industry in the country is expected to cross $2.5 billion mark by 2012. “Indian pharmaceutical offshoring industry is set to become a $2.5 billion opportunity by 2012,''a study titled 'Indian Pharmaceutical offshoring industry' done by the management consulting firm Zinnov said. One of the key factors driving the offshoring wave is increasing research and development (R&D) costs incurred in both development and manufacturing of new drugs, which in-turn is compelling global pharmaceutical organisations in the US and EU to look fo r new low cost R&D destinations such as India and China, it added. Basic production cost of medicines in India is up to 50 per cent lower than in the US. A US Food and Drug Authority (FDA) approved plant can be constructed in India at 30-50 per cent lower costs, compared with established markets, the study pointed out. Out of the projected $2.5 billion market by 2012, contract manufacturing accounts for the maximum share as the total manufacturing outsourcing business in India will cross $900 million by 2010 followed by clinical trials which are growing at the compound annual growth rate of 31 per cent and are set to become $608 million industry by 2012. India's rich talent pool, nearly 13.5 million science graduates growing at the rate of 36 per cent, plays a major role in the growth of outsourcing development process, the study said. - PTI
Prev: Rupee ends weaker Business Line | NUS Index | |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line
|